Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib vs Chemotherapy in FGFR-positive Urothelial Carcinoma
NCT03410693Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of rogaratinib in urothelial carcinoma (UC), sponsored by Bayer. Started May 2018; status: completed.
02
Drugs
rogaratinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03410693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03410693.